Bright Minds Biosciences Inc. (DRUG)
| Market Cap | 769.03M +149.9% |
| Revenue (ttm) | n/a |
| Net Income | -17.26M |
| EPS | -2.01 |
| Shares Out | 9.86M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 127,793 |
| Open | 79.48 |
| Previous Close | 79.48 |
| Day's Range | 78.73 - 84.43 |
| 52-Week Range | 38.00 - 123.75 |
| Beta | 0.09 |
| Analysts | Strong Buy |
| Price Target | 170.03 (+102.32%) |
| Earnings Date | Aug 20, 2026 |
About DRUG
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neurop... [Read more]
Analyst Summary
According to 7 analysts, the average rating for DRUG stock is "Strong Buy." The 12-month stock price target is $170.03, which is an increase of 102.32% from the latest price.
News
Bright Minds Biosciences Registration statement: Q3 2026
Bright Minds Biosciences filed a registration statement on August 14, 2026, providing details about a securities offering with the SEC.
Bright Minds Biosciences Registration statement: Q3 2026
Bright Minds Biosciences filed a registration statement on August 14, 2026, providing details about a securities offering with the SEC.
Vistagen Appoints Douglas J. Williamson to its Board of Directors
SOUTH SAN FRANCISCO, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to dev...
New Options Listings: Bright Minds Biosciences (DRUG)
New Options Listings: Bright Minds Biosciences (DRUG)
Bright Minds Biosciences Transcript: Jefferies Global Healthcare Conference 2026
Lead 5-HT2C agonist BMB-101 showed robust efficacy and safety in phase II for absence seizures and DEE, with phase III trials starting later this year and data expected in 2024. Market potential is significant, and the asset offers key advantages over competitors in dosing, safety, and mechanism.
Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 ago...
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline
Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric conditions in a pre-clinical model.
Bright Minds price target raised to $220 from $190 at Piper Sandler
Piper Sandler raised the firm’s price target on Bright Minds (DRUG) to $220 from $190 and keeps an Overweight rating on the shares. The firm caught up with Bright Minds…
Bright Minds Biosciences Registration statement: Q2 2026
Bright Minds Biosciences filed a registration statement on May 19, 2026, providing details about a securities offering with the SEC.
Bright Minds Biosciences Registration statement: Q2 2026
Bright Minds Biosciences filed a registration statement on May 19, 2026, providing details about a securities offering with the SEC.
DRUG Initiates Coverage On Bright Minds Biosciences -- Price Target Announced
DRUG Initiates Coverage On Bright Minds Biosciences -- Price Target Announced
Bright Minds initiated with a Buy at Jefferies
Jefferies initiated coverage of Bright Minds (DRUG) with a Buy rating and $145 price target The firm says the company’s oral BMB-101 is a potential best-in-class 5-HT2C agonist. BMB-101 has
Bright Minds Biosciences Inc at TD Cowen Healthcare Conference Transcript
Bright Minds Biosciences Inc at TD Cowen Healthcare Conference Transcript
Bright Minds Biosciences Transcript: TD Cowen 46th Annual Health Care Conference
BMB-101 demonstrated strong efficacy and safety in refractory seizure disorders, with phase III trials in epilepsy and Prader-Willi syndrome underway. Both indications are seen as multi-billion dollar opportunities, and recent financing supports multiple upcoming clinical readouts.
Bright Minds price target raised to $145 from $115 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Bright Minds (DRUG) to $145 from $115 and keeps a Buy rating on the shares. The firm says the BREAKTHROUGH Phase 2
Bright Minds Biosciences to Present at Upcoming Conferences
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 ag...
BTIG Maintains Buy Rating for Bright Minds Biosciences (DRUG) with $147 Target | DRUG Stock News
BTIG Maintains Buy Rating for Bright Minds Biosciences (DRUG) with $147 Target | DRUG Stock News
Bright Minds price target lowered to $126 from $142 at Baird
Baird lowered the firm’s price target on Bright Minds (DRUG) to $126 from $142 and keeps an Outperform rating on the shares. The firm updated its model following Q4 results
Bright Minds Biosciences Registration statement: Q1 2026
Bright Minds Biosciences filed a registration statement on February 11, 2026, providing details about a securities offering with the SEC.
Bright Minds Biosciences Registration statement: Q1 2026
Bright Minds Biosciences filed a registration statement on February 11, 2026, providing details about a securities offering with the SEC.
Bright Minds Biosciences Announces Closing of US$175 Million Public Offering
NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) today closed its recently announced public offering of 1,945,000 ...
Bright Minds Biosciences (DRUG) Prices $175M Public Offering
Bright Minds Biosciences (DRUG) Prices $175M Public Offering
Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock
NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces the pricing of its previously announced public offering...
Bright Minds Biosciences, Praxis Precision Medicines And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Full story available on Benzinga.com
Bright Minds price target raised to $142 from $82 at Baird
Baird raised the firm’s price target on Bright Minds (DRUG) to $142 from $82 and keeps an Outperform rating on the shares. The firm updated its model following the release